

09-14-01

410 Rec'd PTO

10 SEP 2001

GPO 2004  
DOC 59

PATENT

Attorney Docket No. 350013-73



## CERTIFICATE OF MAILING

I hereby certify that on September 10, 2001 this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to the Box No Fee Amendment, Commissioner of Patents, Washington, D.C. 20231.

37 CFR 1.8(a)  
 with sufficient postage  
 as first class mail

37 CFR 1.10  
 as "Express Mail Post Office  
 to Addressee" Mailing Label  
 No. EL585710041US

VALERIE MATA

(Type or print name of person mailing paper)

(Signature of person mailing paper)

Serial No. 09/763,913

Filed: October 23, 2000

Title: Host-Encoded Protein  
 Expressed on Marek's Disease  
 (MDV)-Infected Cells and Antibody,  
 Thereto

Applicant: Burgess, et al.

Group Art Unit No. Unknown

Examiner: Francine Young

RECEIVED  
 SEP 25 2001  
 Technology Center 2600

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents & Trademarks  
 BOX NO FEE AMENDMENT  
 Washington, D.C. 20231

**SUBMISSION OF SUBSTITUTE SEQUENCE LISTING, COMPUTER READABLE COPY  
 AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY  
 INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
(37 CFR §§ 1.821-1.825)**

Sir/Madam

Applicants enclose herewith a copy of the SUBSTITUTE SEQUENCE LISTING in computer readable (ASCII) form. A paper copy of the SUBSTITUTE SEQUENCE LISTING in compliance with 37 CFR §§ 1.821-1.825 for the nucleotide and amino acid sequences disclosed in the above-referenced application is also submitted herewith.

**STATEMENT THAT COMPUTER READABLE COPY OF  
 THE SUBSTITUTE SEQUENCE LISTING IS THE SAME AS THE  
PAPER COPY OF THE SUBSTITUTE SEQUENCE LISTING**

I hereby state:

1. The computer readable (ASCII) form of the SUBSTITUTE SEQUENCE LISTING submitted in this application is the same as the paper copy of the SUBSTITUTE SEQUENCE LISTING to which it is indicated to relate.
2. All papers accompanying this submission introduce no new matter to the accompanying application.

**VERIFICATION**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of the Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

**The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-2230, a duplicate copy of this paper is enclosed.**

Respectfully submitted,



Guy Porter Smith, Reg. 20,142

**OPPENHEIMER WOLFF & DONNELLY LLP**  
2029 Century Park East, Suite 3800  
Los Angeles, California 90067  
(310) 788-5000

Dated: September, 10, 2001.



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/673913	BURGESS	S 350013-73
INTERNATIONAL APPLICATION NO.		PCT/GB99/01238
1.A. FILING DATE		PRIORITY DATE
22 MAR 99		29 APR 98

DATE MAILED: 10 Aug 2001

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.

This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).

A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).

A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

Other: \_\_\_\_\_

RECEIVED  
Technology Center 2600  
SEP 10 2001

**APPLICANT MUST PROVIDE:**

An initial or substitute computer readable form (CRF) of the "Sequence Listing."

An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

(703) 308-4216, for Rules interpretation,  
(703) 308-4212, for CRF submission help,  
(703) 287-0200, for PatentIn software help.

  
Francine Young  
Telephone: 703-305-3662